LAQV-REQUIMTE, FCT- University NOVA of Lisbon (Lisbon, Portugal)

LAQV-REQUIMTE, FCT- University NOVA of Lisbon (Lisbon, Portugal)

Hugo Miguel Santos, PhD

LAQV-REQUIMTE, FCT- University NOVA of Lisbon (Lisbon, Portugal)

Elisabete Oliveira, PhD

LAQV-REQUIMTE, FCT- University NOVA of Lisbon (Lisbon, Portugal)

Javier Fernández Lodeiro, PhD

LAQV-REQUIMTE, FCT- University NOVA of Lisbon (Lisbon, Portugal)

University of Trás-os-Montes and Alto Douro, ECVA-DGB | LAQV-REQUIMTE (Portugal)

Hira Nakhasi, PhD

U.S. Food and Drug Administration (USA)

Laia Solano-Gallego, PhD

Universitat Autònoma de Barcelona (Spain)

Christian Bogdan, PhD

University Hospital of Erlangen and Friedrich-Alexander-University (FAU) (Germany)

Jeronimo Carnes, PhD

Leti Pharma (Spain)

Hiro Goto, PhD

Department of Preventive Medicine, and Instituto de Medicina Tropical, Faculdade de Medicina, Universidade de São Paulo (Brazil)

Lars Gille, PhD

University of Veterinary Medicine, Vienna (Austria)

Sergi Segarra, PhD

Bioiberica (Spain)

Ingo Schäfer, PhD

Laboklin GmbH & Co. KG, Department of Clinical Pathology, Bad Kissingen, Bavaria (Germany)

Albert Descoteaux, PhD

INRS (Canada)

Dan Zilberstein, PhD

Technion – Israel Institute of Technology (Israel)

Márcia Dalastra Laurenti, PhD

Medical School, University of São Paulo, São Paulo (Brazil)

Marie Lipoldová, PhD

Charles University in Prague (Czech Republic)

Carolina Rodriguez-Cariño, PhD

Veterinary Pathologist, Clinical Pathology Department, IDEXX laboratories Iberia, Barcelona (Spain)

Pegine Walrad, PhD

York Biomedical Research Institute, York (UK)

Paul Denny, PhD

Durham University, Durham (UK)

Sanjai Nagendra, MD

Medical Director Center for Esoteric Testing and Atlantic Regional Labs, Burlington (USA)

Angela Kaysel Cruz, PhD

São Paulo University, São Paulo (Brazil)

Xavier Fernàndez Busquets, PhD

Institute for Bioengineering of Catalonia, Barcelona (Spain)

The protein aggregation dye YAT2150 is a potent antileishmanial agent

Ger van Zandbergen, PhD

Federal Institute for Vaccines and Biomedicines, Berlin (Germany)

William Kerr, PhD

Ospedale Policlinico San Martino/SUNY Upstate Medical University, New York (USA)

Inhibition of the SHIP1/2 paralogs to combat infection and disease